Table 1.
Baseline characteristics
| Characteristics | Escalation Cohort | Expansion Cohort | All Patients (N = 45) |
|---|---|---|---|
| (n = 29) | (n = 16) | ||
| Median age, y (range) | 58 (34–79) | 60 (44–74) | 60 (34–79) |
| Male gender, n (%) | 19 (66) | 13 (81) | 32 (71) |
| KPS score, n (%) | |||
| 100 | 8 (28) | 5 (31) | 13 (29) |
| 90 | 12 (41) | 6 (38) | 18 (40) |
| 80 | 7 (24) | 3 (19) | 10 (22) |
| 70 | 2 (7) | 2 (13) | 4 (9) |
| Surgery type, n (%) | |||
| Partial or total resection | 22 (76) | 13 (81) | 35 (78) |
| Biopsy | 7 (24) | 3 (19) | 10 (22) |
| EGFR status, n/Na (%) | |||
| Amplification (amplified/patients tested) | 8/26 (31) | 7/12 (58) | 15/38 (39) |
| EGFRvIII mutation (mutated/patients tested) | 5/27 (19) | 7/14 (50) | 12/41 (29) |
| (EGFRvIII mutated and EGFR amplified)/amplified | 5/8 (63) | 6/7 (86) | 11/15 (73) |
| EGFR overexpression/patients tested | 7/27 (26) | 7/14 (50) | 14/41 (34) |
| MGMT methylation status, n/Na (%) | |||
| Methylated | 5/21 (24) | 4/9 (44) | 9/30 (30) |
| Unmethylated | 16/21 (76) | 5/9 (56) | 21/30 (70) |
| MCP class, n/Na (%) | |||
| 2 | 2/17 (12) | 2/8 (25) | 4/25 (16) |
| 3 | 13/17 (76) | 6/8 (75) | 19/25 (76) |
| 4 | 1/17 (6) | 0/8 (0) | 1/25 (4) |
a n = number of patients with that characteristic, N= total number of patients in that group.
EGFR, epidermal growth factor receptor; KPS, Karnofsky performance status; MCP, molecular classification predictor; MGMT, O-6-methylguanine-DNA methyltransferase.